Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.

Journal of Chemotherapy

Volumn 22, Issue 4, 2010, Pages 264-266

  Garau, J ^a   Fritsch, A ^b   Arvis, P ^c   Read, R C ^d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b BAYER PHARMA AG   (Germany)

^c Bayer Schering Pharma   (France)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Clinical trials; Community acquired pneumonia; Legionella; Moxifloxacin

Indexed keywords

ALATROFLOXACIN; AMOXICILLIN; CEFTRIAXONE; CLARITHROMYCIN; CLAVULANIC ACID; ERYTHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; TROVAFLOXACIN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BACTERIUM CULTURE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LEGIONELLA; MALE; OUTCOME ASSESSMENT; SEROLOGY; URINALYSIS;

EID: 78650202110     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.4.264     Document Type: Article

References (10)

1. Diederen BMW. Legionella pp. and Legionnaires Disease. J Infect 2008; 56: 1-12.
2. von Baum H, Ewig S, Marre R, Suttorp N, Gonschior S, Welte T et al, Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis 2008; 46: 1356-1364.
3. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell D, Dean NC et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-S72.
4. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180.
5. Jonas D, Engels I, Friedhoff C, Spitzmüller B, Daschner FD, Frank U. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 2001; 47: 147-152.
6. File TM, Larsen LS, Fogarty CM, Schechter RB, Peloquin S, Choudhri SH et al. Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneumonia in hospitalized patients. Todays Ther Trends 2001; 19: 251-270
7. Weite T, Petermann W, Schurmann D, Bauer TT, Reimnitz P and the MOXIRAPID Study Group. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41: 1697-1705.
8. Finch R. Schürmann D, Collins O, Kubin R, McGivern J, Bobbaers H et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-1754.
9. Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study-a randomized clinical trial. Clin Infect Dis 2008; 46: 1499-1509.
10. Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175: 1086-1093.